The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

Please provide your email address to receive an email when new articles are posted on . Use of race-specific lung function equations resulted in misclassification of patients with ILD eligible for ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

EULAR—The European Alliance of Associations for Rheumatology—has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...

Contact or have your doctor's office contact our administrator at (205) 934-7557. In order to complete your evaluation at UAB in a timely, efficient and comprehensive manner, please arrange for the ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving nintedanib demonstrated slowed function deterioration compared with those receiving placebo.

Background: Vitamin D is a steroid hormone with pleiotropic effects including immune system modulation, lung tissue remodeling, and bone health. Vitamin D deficiency has been implicated in the ...

PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...